BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Frasson, I., Diamante, L., & Zangrossi, M. (2023). Identification of druggable host dependency factors shared by multiple sars-cov-2 variants of concern. bioRxiv. Added by: Dr. Enrique Feoli (12/01/2023, 10:32) Last edited by: Dr. Enrique Feoli (12/01/2023, 10:33) |
 |
| Resource type: Journal Article DOI: 10.1101/2023.01.09.523209 BibTeX citation key: Frasson2023 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: COVID-19 Creators: Diamante, Frasson, Zangrossi Collection: bioRxiv |
Views: 3/154
|
| Abstract |
|
The high mutation rate of SARS-CoV-2 leads to emergence of several variants, some of which are resistant to vaccines and drugs targeting viral elements. Targeting host dependency factors {textendash} cell proteins required for viral replication - would help avoid resistance. However, whether different SARS-CoV-2 variants induce conserved cell responses and exploit the same core host factors is still unclear.We compared three variants of concern and observed that the host transcriptional response was conserved, differing only in kinetics and magnitude. By CRISPR screening we identified the host genes required for infection by each variant: most of the identified genes were shared by multiple variants, both in lung and colon cells. We validated our hits with small molecules and repurposed FDA-approved drugs. All drugs were highly effective against all tested variants, including delta and omicron, new variants that emerged during the study. Mechanistically, we identified ROS production as a pivotal step in early virus propagation. Antioxidant drugs, such as N-acetyl cysteine (NAC), were effective against all variants both in human lung cells, and in a humanised mouse model. Our study strongly supports the immediate use of available antioxidant drugs, such as NAC, as a general and effective anti-COVID-19 approach.Competing Interest StatementThe authors have declared no competing interest.
|